Eurosurv. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Net

[tetano]

• Anne J Huiberts[SUP]1[/SUP] , Christina E Hoeve[SUP]1[/SUP] , Brechje de Gier[SUP]1[/SUP] , Jeroen Cremer[SUP]1[/SUP] , Bas van der Veer[SUP]1[/SUP] , Hester E de Melker[SUP]1[/SUP] , Janneke HHM van de Wijgert[SUP]1,2[/SUP] , Susan van den Hof[SUP]1[/SUP] , Dirk Eggink[SUP]1,*[/SUP] , Mirjam J Knol[SUP]1,*[/SUP]

We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8–2.6).
​

https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.10.2400109

 

[sharon sanders]

bump this